|
www.Xtremepicks.Com: Xtremepicks Alerts November 18, 2009 : NTWK, AVII, CDCS and VRSN
(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts include NetSol Technologies, Inc. "NetSol" (NASDAQ: NTWK), AVI BioPharma, Inc. (NASDAQ: AVII), CDC Software (NASDAQ: CDCS) and VeriSign, Inc. (NASDAQ: VRSN)
NetSol Technologies, Inc. "NetSol" (NASDAQ: NTWK) trading at $0.91 per share on trading volume of 14,600 shares.
In a press release out on November 18, NetSol Technologies Announces Additional Services Contract With BMW Group Financial Services
Service Contract for Independent Systems Review and Testing Services of BMW's Newest Financial Application
CALABASAS, CA, Nov 18, 2009 -- NetSol Technologies, Inc. "NetSol" (NASDAQ: NTWK) (NASDAQ DUBAI: NTWK), a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide, today announced the signing of an Independent System Review (ISR) and Testing Services contract with BMW Group Financial Services - Asia Pacific region. The contract calls for the comprehensive testing of a newly developed financial application suite to be deployed in more than eight countries in Asia Pacific and South Africa. The project is the second in a series of contracts signed by NetSol's ISR services group with BMW after the successful delivery of ISR services to BMW Group Financial Services Japan last year.
About NetSol Technologies, Inc.
NetSol Technologies, Inc. (NASDAQ: NTWK) (NASDAQ DUBAI: NTWK) is a worldwide provider of global business services and enterprise application solutions. Since its inception in 1995, NetSol has used its BestShoring(R) practices and highly experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions. Specialized by industry, these product and services offerings include credit and finance portfolio management systems, hospital/healthcare information management systems (HIMS), SAP consulting and services, custom development, systems integration, and technical services for the global Financial, Healthcare, Insurance, Energy, and Technology markets. NetSol's commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by fewer than 100 companies worldwide. NetSol Technologies' clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies. Headquartered in Calabasas, California, NetSol Technologies has operations and offices in Adelaide, Bangkok, Beijing, Lahore, London, and San Pedro Sula.
AVI BioPharma, Inc. (NASDAQ: AVII) trading at $1.54 per share on trading volume of 107,629 shares.
In a press release out on November 18, AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
BOTHELL, WA, Nov 18, 2009 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming Transformational Medical Technologies Initiative (TMTI) Industry Day taking place in Dallas, Texas.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junin, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.
CDC Software (NASDAQ: CDCS) trading at $10.00 on a volume of 100 shares
In a press release out on November 18, CDC Software to Hold Third Quarter 2009 Earnings Call on November 23, 2009 at 8:00 AM EST
ATLANTA & HONG KONG, Nov 18, 2009 -- CDC Software (NASDAQ: CDCS) will hold a conference call to discuss the company's third quarter 2009 earnings and operating results on Monday, November 23, 2009, at 8:00 A.M. EST. An earnings release will precede the call, posting to the wires on Sunday, November 22, 2009.
About CDC Software
CDC Software (NASDAQ: CDCS) is a provider of enterprise software applications designed to help organizations deliver a superior customer experience while increasing efficiencies and profitability. CDC Software's product suite includes: CDC Factory (manufacturing operations management), Ross ERP (enterprise resource planning) and SCM (supply chain management), CDC Supply Chain (supply chain management ,warehouse management and order management), Pivotal CRM and Saratoga CRM (customer relationship management), Respond (customer complaint and feedback management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Platinum HRM (human resources) and business analytics solutions.
VeriSign, Inc. (NASDAQ: VRSN) trading at $22.57 on a volume of 407,004 shares
In a press release out on November 18, VeriSign Provides Digital Identity Management to Aerospace and Defense Industry
Managed PKI Service Built on CertiPath Standards Reduces Costs, Risks and Need for Additional Infrastructure
MOUNTAIN VIEW, CA, Nov 18, 2009 -- VeriSign, Inc. (NASDAQ: VRSN), the trusted provider of Internet infrastructure for the networked world, today announced VeriSign's Managed Public Key Infrastructure (PKI) service now enables aerospace and defense (A&D) organizations to quickly and cost-effectively deploy a PKI solution. VeriSign's Managed PKI helps reduce customer risk and minimizes expenses, eliminating the up-front costs of acquiring systems, software and people to operate an in-house Certificate Authority (CA) for cross-certification with CertiPath.
About VeriSign
VeriSign, Inc. (NASDAQ: VRSN) is the trusted provider of Internet infrastructure services for the networked world. Billions of times each day, VeriSign helps companies and consumers all over the world engage in communications and commerce with confidence. Additional news and information about the company is available at www.verisign.com.
Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.
Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Homepage ]
|
Home
Featured Article Archives
eNews
RSS FEED
